Purpose Adult medulloblastoma is a rare disease treated according to the current pediatric treatment guidelines. This retrospective analysis investigated the clinical outcomes and prognostic factors of adult medulloblastoma patients, who received multimodal therapy at our institution. Methods Treatment charts of all patients over the age of 15 years of age with de novo medulloblastoma, who had been treated at our institution between 2001 and 2014, were retrospectively analyzed. Patients' demographic parameters, initial symptoms, treatment modalities, toxicities, and survival outcomes were investigated. Results In all, 21 patients with a median age of 30.2 years were identified. The most frequent histologies were desmoplastic and classic, and the most common molecular subtype was sonic hedgehog (SHH). After tumor resection, all patients received craniospinal irradiation (median dose 35.2 Gy) and a boost to the posterior fossa (median dose 19.8 Gy). Simultaneous chemotherapy with vincristine was given to 20 patients and sequential chemotherapy to 15 pa- German Cancer Consortium (DKTK), Munich, Germany tients. The most common side effects were hematological toxicities. Median overall survival (OS) has not been reached after a median follow-up of 92 months. Estimated 5-and 10-year OS was 89 and 80%, respectively. Estimated 5-and 10-year progression-free survival (PFS) was 89 and 81%, respectively. In univariate analysis, a shorter interval between tumor resection and end of irradiation was significantly associated with improved OS and PFS, anaplastic histology with worse OS and PFS. Conclusions The combined modality treatment showed a good outcome in adults with medulloblastoma. Treatment time was revealed to be prognostic and should be kept as short as possible.
Medulloblastoma in adults is a rare disease with an incidence of 0.5-1 per million, whereas it is the most common malignant brain neoplasm in children [1] . Therapy of adult medulloblastoma is mostly based on pediatric treatment protocols although the biology is different [1] . The only prospective study on adult medulloblastoma investigated the effect of radiotherapy alone for standard-risk patients and upfront chemotherapy followed by radiotherapy and adjuvant chemotherapy for high-risk patients and found 5-year overall survival rates of 80 and 73%, and 5-year progression-free survival rates of 80 and 69%, respectively [2] . Other available data about the treatment of adult medulloblastoma is retrospective. The prospective NOA-07 study investigates a combination of resection, chemoradiotherapy with vincristine and sequential chemotherapy with vincristine/cisplatin/CCNU (CCNU: lomustine) in adult medulloblastoma patients. Recruitment of the study is closed and results are still awaited. In recent years, three distinct molecular variants of adult medulloblastoma have been described. The sonic hedgehog (SHH) subtype is the most common and might be treated with targeted agents in future. The subgroup 4 and Wnt/Wingless (WNT) tumors seem to have a worse prognosis in adults [3] . Group 3 medulloblastoma mainly occurs in infants or children, while occurrence in adult patients is extremely rare.
We conducted a retrospective analysis to contribute our data to the literature and to evaluate possible subgroups that may profit most from novel agents and individualized therapy regimens. Outcome and prognostic factors of adult medulloblastoma patients treated with multimodal therapy at our institution were investigated.
Methods
Treatment charts of all patients with de novo medulloblastoma over the age of 15 years of age (according to [4, 5] ) who had been treated at our institution between 2001 and 2014 were retrospectively analyzed. The investigated parameters include the following: age, gender, Karnofsky performance status (KPS), histology, initial symptoms, initial diagnostics (neuroimaging and cerebrospinal fluid sampling), location, stage according to the modified Chang Staging System [6] , and risk group of the tumor (highrisk: evidence of tumor dissemination initially and/or postoperative residual disease >1.5 cm 2 and/or unfavorable histopathology [large cell/anaplastic]; standard-risk: other), treatment modalities, dimension of tumor residues after resection, radiotherapy parameters, chemotherapy protocol, toxicities of the treatments according to Common Terminology Criteria for Adverse Events (CTCAE) version 4, use of supportive therapies, and survival outcomes.
Statistical analyses were performed with IBM SPSS Statistics, Version 23 (IBM, Armonk, NY, USA). Patient demographics were calculated as absolute and relative frequencies. The Kaplan-Meier analysis was performed to assess progression-free survival (PFS) and overall survival (OS). PFS was defined as the interval between the date of first diagnosis and the date of disease progression of the medulloblastoma within the central nervous system or the date of the last follow-up. OS was considered as the interval between the date of first diagnosis and the date of death from any cause or the date of the last follow up. The logrank test was used to assess the influence of various factors on survival. A two tailed p-value of <0.05 was considered significant.
The institutional review board approved this analysis and all patients signed informed consent prior to the start of therapy. 
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Results
Patient characteristics
A total of 21 patients (11 males and 10 females) with de novo medulloblastoma were identified. Median age was 30.2 years (range 16.5-45.6 years). At therapy start 19 patients had a good KPS (70-100%, ECOG 0-1) and two had a KPS of 60% (ECOG 2). Initial symptoms and further patient characteristics are summarized in Table 1 . Magnetic resonance imaging (MRI) of the brain and spine was done in all patients, cerebrospinal fluid (CSF) sampling was performed in 5 patients with suspicion of leptomeningeal dissemination, and atypical cells were found in 2 of them. The most frequent histologies were classic in 8 patients (38.1%) and desmoplastic in 11 patients (52.4%); the most common molecular subgroup was SHH in 13 patients (61.9%). All patients with desmoplastic histology belonged to the SHH subgroup. Of those tumors with classic histology two were grouped in the molecular SHH subgroup, three in group 4, one in WNT, and two are unknown. A total of 15 patients were considered as standard-risk patients and 4 as highrisk patients; one because of anaplastic histology, one because of metastases, one because of postoperative residual disease >1.5 cm 2 , and one because of both. One patient had a metastasis at the level of the fourth lumbar vertebra and the other had one that reached from the first lumbar vertebra to the sacrum. Two patients could not be classified due to missing data on the resection status.
Treatment modalities and toxicities
A CONSORT (Consolidated Standards of Reporting Trials) diagram of the combined modality treatment of the 21 patients is presented in Fig. 1 .
All patients underwent tumor resection, which was gross total in 14 patients. Three patients had postoperative residual disease Ä1.5 cm 2 and in two a tumor residue >1.5 cm 2 was detected. Resection status was unknown in 2 patients. In all, 17 patients had no postoperative complications, 3 patients underwent cerebrospinal fluid diversion surgery due to hydrocephalus within 60 days after operation, and 1 patient needed recraniotomy because of cerebral bleeding. After tumor resection, all patients received craniospinal irradiation (CSI) of the entire brain and spine. The median interval between operation and start of CSI was 24 days (range 9-55 days). CSI was applied with a median dose of 35.2 Gy (range 23.4-39.0 Gy) in single doses of 1.5-1.8 Gy. The different CSI dosage schemes are listed in Table 2 among other treatment parameters. After CSI, a boost was given to the whole posterior fossa with single doses of 1. CCNU chlorethyl-cyclohexyl-nitroso-urea (lomustine), q4w every 4 weeks tional boost of these regions with 1.5-1.8 Gy fractions to 13.5-14.4 Gy total dose. Radiotherapy planning was simulator-based (2D-RT) in 13 cases and three dimensional (3D-RT) in 8 cases. In 11 of the 13 cases with simulatorbased planning of the CSI, the additional boost was applied as 3D-RT. Positioning during irradiation was prone in 9 patients and supine in 8. The median duration between first and last irradiation was 48 days (range 29-69 days) and 73 days (range 48-100 days) between tumor resection and the end of irradiation treatment. Simultaneous chemotherapy with vincristine 1.5 mg/m ² body surface (maximum 2 mg absolute) was applied weekly during radiotherapy in 20 patients. The acute side effects of chemoradiotherapy are listed in Table 3 . The most common side effects were hematological toxicities.
Sequential chemotherapy with cisplatin/vincristine/ CCNU q4w (every 4 weeks) was applied in 11 patients with a maximum number of cycles of 8. One of the 11 patients received only 7 cycles because of pancytopenia and polyneuropathy, a second received 6 cycles also due to polyneuropathy, and in another patient the chemotherapy dose had to be reduced to 75% after 4 cycles due to vertigo. Cisplatin 70 mg/m 2 q4w was given to 2 patients. Cisplatin/ CCNU was applied in 1 patient; but cisplatin had to be substituted with carboplatin after 4 given cycles because of tinnitus and hearing impairment. One patient received sequential chemotherapy without any further information. Two patients received no sequential chemotherapy at all. In 4 patients, it was unknown whether sequential chemotherapy was applied or not.
Survival and prognostic factors
Median OS was not reached after a median follow-up of 92 months. Estimated 5-and 10-year OS for all patients was 88.7 and 79.8% (Fig. 2) , for standard-risk patients 90.9 and 79.5%, respectively, and for high-risk patients both were 66.7%.
Estimated 5-and 10-year PFS was 88.7 and 81.3% for all patients (Fig. 3) , 66.7 and 66.7% for high-risk patients, and 90.9 and 80.8% for standard-risk patients, respectively. Three patients suffered from a relapse. One patient with anaplastic medulloblastoma had a recurrent tumor in the right cerebellum after 17 months and died 4 weeks later. The tumor of another patient relapsed at the lateral ventricles after 44 months and he died 2 weeks after diagnosis of the recurrent disease. The third patient suffered from a relapse in the cerebellum 70 months after first diagnosis and died 2 years after diagnosis of the relapse.
In univariate analysis a shorter interval (Ä73 days) between tumor resection and end of irradiation was significantly associated with improved OS (p = 0.031) and PFS (p = 0.049) (Fig. 4) , anaplastic histology with worse OS CSF cerebrospinal fluid, L lumbar vertebra, 2D-RT simulator-based radiotherapy planning, 3D-RT three-dimensional radiotherapy planning, CCNU chlorethyl-cyclohexyl-nitroso-urea (lomustine) and PFS (p < 0.001). The results of univariate analysis of other prognostic factors are summarized in Table 4 .
Discussion
The outcome results of this investigation are in line with those presented in the only prospective study mentioned above [2] and other retrospective analyses, e. g., [7] . In our patient group with chemoradiotherapy, mostly followed by adjuvant chemotherapy 5-year OS rates of 88, 91, and 67% were reached for all, standard-risk, and high-risk patients, respectively. In the study by Brandes et al. [2] , the 5-year OS for standard-risk patients treated with radiotherapy alone seems somewhat worse (80%), but slightly improved for high-risk patients treated with a chemotherapy-radiotherapy-chemotherapy sequence (73%), compared to our data. This may hint at an advantage for chemotherapy in standard-risk patients as well. One of the rare studies with long-term follow-up assessed this question and found 5-, 10-, and 15-year survival rates of 100, 79, and 60% in standard-risk patients treated with radiotherapy alone, and 100, 100, and 100% in patients treated with radiotherapy plus chemotherapy [8] . A retrospective study with 31 patients treated with radiotherapy alone or in combination with adjuvant chemotherapy with a median follow-up of 27 months reported 3-and 5-year disease-free survival rates of 85 and 51%, respectively [9] . In our patient cohort, 5-and 10-year PFS rates of 89 and 81% were reached. Recurrences in adult medulloblastoma patients usually occur late. Only the tumor with anaplastic histology recurred 1.4 years after diagnosis, the others after 3.7 and 5.8 years. In another retrospective analysis [10] , 45% of all recurrences were recognized more than 4 years after initial surgery predominantly in the posterior fossa.
In adult medulloblastoma, the following molecular subgroups have been described [3, 11] : the SHH subgroup has been found in more than half of the cases. In our analysis, 13 of the 17 cases (76.5%) with the known molecular subgroup belonged to the SHH group. Subgroup 3 tumors are very rare in adults, and there were none in our patient cohort. Regarding prognosis, it is known that adult subgroup 4 and WNT tumors have a worse prognosis than their pediatric counterparts. In our analysis, with only one WNT and three group 4 tumors we were not able to identify significant survival differences between the molecular subgroups [12] . Only anaplastic histology was prognostic for worse PFS and OS, as others also described before [13] even though caution must be taken because it was based on one patient in our analysis. Our findings that all desmoplastic tumors had the SHH subgroup and that all adult molecular subgroups were found in the group of patients with classic histology is in line with other studies [1, 3] .
Complete surgery rates are relatively high in our patient cohort, with no residual disease in 67% and residuals Ä1.5 cm 2 in 14%. Total or near total resection is usually reported in approximately 60% [1] . This might be a selection bias only partly accounted for by the risk grouping. All of the patients included in this analysis had CSI (with varying dose schemes) followed by a boost to the posterior fossa to a total dose of 54 Gy which can be considered presently as standard [1] . As only 2 patients had CSI with a reduced dose of 23.4 Gy, this analysis cannot answer the question whether a dose reduction in a special subgroup of patients is justified. To reduce radiotherapy induced toxicities, proton therapy might be an option [14] [15] [16] [17] . Our analysis revealed treatment time between surgery and end of radiotherapy to be a crucial prognostic factor. An early start of radiotherapy and a lack of radiotherapy interruptions must be stressed to be mandatory in treatment recommendations [18] . The latter might be especially important [19] . Others found the radiotherapy treatment field (CSI + posterior fossa boost) and CSI dose ≥30 Gy to be K prognostic [20] . Compared to radiotherapy, chemotherapy application (substances and sequence) is more controversial [21] , mainly because of anticipated toxicity in adult patients. In our series, simultaneous chemoradiotherapy led to one grade III anemia, one grade III and one grade IV thrombocytopenia, and eight grade III and one grade IV leukopenia. Sequential chemotherapy had to be modified in 4 of 14 patients. Evaluation of adult observational patients treated within the pediatric HIT 2000 protocol showed that maintenance chemotherapy was feasible, but peripheral neuropathy (74%) and hematotoxicity (55%) were more common in adults [22] . The importance of chemotherapy as part of multimodal first-line therapy, even for M0 patients with high-dose CSI was stressed by others [4, 23] .
Limitations of this analysis are its retrospective nature and the small number of cases, which are sources of potential bias. However, prospective randomized trials will hardly be conducted for this rare disease. Pooling of retrospective data from several centers might be a feasible and preferable alternative to better identify patients who might profit from individualized therapy regimens [24] .
Conclusion
The combined modality treatment showed a good outcome in adults with medulloblastoma. Treatment time was revealed to be prognostic and should be kept as short as possible. Significant outcome differences between the molecular subgroups could not be identified.
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